– USA, CA – Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, today announced the appointment of Dr. John Quisel (J.D., Ph.D.) to its Board of Directors.
“Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team. Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quisel’s appointment enhances our ability to get seralutinib to patients,” said Chairman, Co-Founder and CEO, Faheem Hasnain.
About Dr. John Quisel
Dr. Quisel is currently the President and CEO of Disc Medicine, a position he has held since January 2020 during which time, the company established a multi-product portfolio of hematology programs and became a publicly traded company.
“I am honored to join Gossamer’s Board at this pivotal moment for the Company,” said Dr. Quisel. “Despite recent advances, PAH remains a progressive and fatal disease, and for this reason I am excited to rejoin the fight against PAH with Gossamer.”
Previously, Dr. Quisel was EVP and CBO at Acceleron Pharma, where he spent more than thirteen years in various senior roles helping to build the company from a privately held startup to a fully integrated, publicly-traded company. Dr. Quisel led the initiative to re-acquire rights for etanercept for pulmonary hypertension from Bristol-Myers Squibb, which eventually led to the acquisition of Acceleron by Merck & Co. for over $11 billion in 2021. During his tenure, Dr. Quisel also served in various roles, including SVP of Corporate Development and General Counsel. Before Acceleron, he was an attorney at the firms Ropes & Gray and Foley Hoag.
Dr. Quisel received an A.B. in biological sciences from Harvard College, an M.Sc. in biology from Stanford University, a Ph.D. in biology from the Massachusetts Institute of Technology, and a J.D. from Harvard Law School.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in and to enhance the lives of patients suffering from pulmonary hypertension.
SOURCE: https://www.gossamerbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
